Cochrane’s Q test did not provide evidence of heterogeneity between CCL18 (p = 0.767), CCL19 (p = 0.093), CCL24 (p = 0.935), CXCL17 (p = 0.210) and prostate cancer. Here, CCL19 is linked to prostate carcinoma.